Beyond Air (NASDAQ:XAIR) entered a definitive agreement for UNIVO Pharmaceutical Industries to acquire control of NeuroNOS Israel, a neurology-focused biopharmaceutical company in which Beyond Air owns approximately 58% of fully diluted shares.
Beyond Air (NASDAQ:XAIR) reported second-quarter 2026 revenue of $1.8 million, broadly unchanged from the prior-year period, while gross margin improved to 13%.
Beyond Air (NASDAQ:XAIR) reported fiscal 2026 revenue of $7.7 million, an increase of 107% year over year.
Beyond Air (NASDAQ:XAIR) reported a surge in third-quarter revenue and a strategic pivot toward its core respiratory business, announcing a binding agreement to divest its autism and neuro-oncology subsidiary to XTL Biopharmaceuticals.
